KRYSTEXXA

This brand name is authorized in United States. It is also authorized in Estonia, Lithuania.

Active ingredients

The drug KRYSTEXXA contains one active pharmaceutical ingredient (API):

1	Pegloticase UNII R581OT55EA - PEGLOTICASE
	Pegloticase is a uric acid specific enzyme which is a recombinant uricase and achieves its therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid. Allantoin is an inert and water soluble purine metabolite; it is readily eliminated, primarily by renal excretion.
	Read more about Pegloticase

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KRYSTEXXA Solution for infusion	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M04AX02		M Musculo-skeletal system → M04 Antigout preparations → M04A Antigout preparations → M04AX Other antigout preparations
Discover more medicines within M04AX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1605002
LT	Valstybinė vaistų kontrolės tarnyba	1069217
US	FDA, National Drug Code	75987-080